Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Directorate Change

29 May 2013 07:00

RNS Number : 7347F
Silence Therapeutics PLC
29 May 2013
 



 

Appointment of chief executive and director of corporate development

29th May 2013

Silence Therapeutics plc (AIM: SLN) announces today the appointment of Ali Mortazavi as chief executive and of Annie Cheng as director of corporate development.

Ali Mortazavi joined Silence in August 2012 as director of corporate strategy and since that time has increasingly taken on the mantle of the CEO role. This included overseeing two fundraisings last year to raise ÂŁ11m for the company and spearheading the ÂŁ19m placing completed in April 2013. Ali has over 17 years of experience in financial services. He started his career as a Technology Analyst at Duncan Lawrie then Credit Lyonnais Securities. In 2001, he co-founded Evolution Securities and ran the principal trading and market making arm, leaving in 2008. He has extensive experience in small companies and has had significant stakes in UK listed technology / biotech ventures.

Annie Cheng (Annie Jia Huey Cheng), age 37, joins the company after working as a strategy consultant for the Company since October 2012. She has 14 years of experience in the healthcare industry, in equity research and consulting with JP Morgan and boutique investment banks in New York and London.

She has been a director of Visible Value LLP, a biotech consultancy, since December 2011 and of Valor Visible Ltd, its associated business, since October 2012.

There are no other matters to disclose regarding her appointment under Rule 17 or Schedule 2 paragraph (g) of the AIM Rules for Companies.

 

Chairman Jerry Randall said: 'Ali brings a wealth of experience in the capital markets as well as small cap companies, and has been instrumental in the development of Silence since he joined. Annie's combination of investor and commercial experience is very valuable.'

 

Silence Therapeutics

Ali Mortazavi, chief executive/Timothy Freeborn, finance director +44 (0)333 988 0140

a.mortazavi@silence-therapeutics.com

t.freeborn@silence-therapeutics.com

 

N+1 Singer

Shaun Dobson/Jenny Wyllie

+44 20 7496 3000

shaun.dobson@n1singer.com

jenny.wyllie@n1singer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGUBPAUPWGQR
Date   Source Headline
4th Jun 20148:32 amRNSNotice of AGM
7th May 20145:05 pmRNSHolding(s) in Company
7th May 201412:03 pmRNSHolding(s) in Company
29th Apr 20144:30 pmRNSResult of Placing
28th Apr 20145:21 pmRNSProposed Placing to raise a minimum of £10 million
28th Apr 20147:00 amRNSGene knockdown in non-human primates
19th Mar 20147:02 amRNSPotential Equity Fundraising
19th Mar 20147:00 amRNSPreliminary Results - Year Ended 31 December 2013
27th Feb 20147:00 amRNSYear end trading update
26th Feb 201412:09 pmRNSHolding(s) in Company
24th Feb 20143:41 pmRNSHolding(s) in Company
23rd Jan 201411:35 amRNSHolding(s) in Company
4th Dec 201311:39 amRNSHolding(s) in Company
22nd Nov 20134:00 pmRNSHolding(s) in Company
21st Nov 20136:25 pmRNSHolding(s) in Company
20th Nov 20135:00 pmRNSGrant of Options and Additional Listing
18th Nov 20137:02 amRNSInvestor Event and Appointment of NOMAD
18th Nov 20137:01 amRNSDirectorate and senior management changes
18th Nov 20137:00 amRNSNew Clinical Trial
8th Nov 20135:33 pmRNSHolding(s) in Company
5th Nov 20137:00 amRNSHolding(s) in Company
23rd Oct 20137:00 amRNSInvestor Day
17th Oct 20135:50 pmRNSHolding(s) in Company
17th Oct 20135:50 pmRNSHolding(s) in Company
17th Oct 20135:50 pmRNSHolding(s) in Company
23rd Sep 20138:33 amRNSHalf Yearly Report
19th Sep 20137:00 amRNSDate of Interim Announcement
30th Aug 20132:46 pmRNSHolding(s) in Company
21st Aug 20137:00 amRNSDirectorate Change
16th Aug 201312:29 pmRNSHolding(s) in Company
8th Aug 20137:00 amRNSAtu027 Phase I/II Update
12th Jul 20134:32 pmRNSHolding(s) in Company
3rd Jul 20137:00 amRNSCancellation of warrants
26th Jun 20132:47 pmRNSResult of AGM
26th Jun 20139:00 amRNSIssue of Options
26th Jun 20137:00 amRNSDirectorate Change
18th Jun 20137:00 amRNSAtu027 update: progression into Phase IIa
7th Jun 20134:35 pmRNSPrice Monitoring Extension
3rd Jun 20134:35 pmRNSPrice Monitoring Extension
3rd Jun 201311:30 amRNSNotice of AGM
29th May 20137:01 amRNSFinal Results
29th May 20137:00 amRNSDirectorate Change
2nd May 20134:52 pmRNSHolding(s) in Company
2nd May 20133:55 pmRNSHolding(s) in Company
2nd May 20133:52 pmRNSHolding(s) in Company
2nd May 20133:26 pmRNSHolding(s) in Company
29th Apr 201312:15 pmRNSResult of EGM
10th Apr 20137:00 amRNSPlacing and Share Consolidation
8th Mar 20137:00 amRNSExercise of warrants
5th Mar 20139:00 amRNSBusiness Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.